Sarepta (SRPT) falls 1.91% to Close at $80.28 on September 14

Equities Staff  |

Sarepta Therapeutics Inc (NASDAQ: SRPT) shares fell 1.91%, or $1.56 per share, to close Tuesday at $80.28. After opening the day at $81.65, shares of Sarepta fluctuated between $82.32 and $80.10. 490,823 shares traded hands a decrease from their 30 day average of 678,412. Tuesday's activity brought Sarepta’s market cap to $6,409,928,823.

Sarepta is headquartered in Cambridge, Massachusetts..

About Sarepta Therapeutics Inc

Sarepta Therapeutics Inc. is leading a revolution in precision genetic medicine and every day is an opportunity to change the lives of people living with raredisease. The Company has built an impressive position in Duchenne muscular dystrophy (DMD) and in gene therapies for limb-girdle muscular dystrophies (LGMDs), mucopolysaccharidosis type IIIA, Charcot-Marie-Tooth (CMT), and other CNS-related disorders, with more than 40 programs in various stages of development. The Company's programs and research focus span several therapeutic modalities, including RNA, gene therapy and gene editing.

Visit Sarepta Therapeutics Inc’s profile for more information.

About The Nasdaq Stock Market

The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world's leading exchange for options volume and is home to the five largest US companies - Apple, Microsoft, Amazon, Alphabet and Facebook.

To get more information on Sarepta Therapeutics Inc and to follow the company’s latest updates, you can visit the company’s profile page here: Sarepta Therapeutics Inc’s Profile. For more news on the financial markets be sure to visit Equities News. Also, don’t forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Chart is provided by TradingView based on 15-minute-delayed prices. All other data is provided by IEX Cloud as of 8:05 pm ET on the day of publication.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

President Biden's New Alliance With Australia and Britain Angers France and European Union
California Governor Newsom Signs Affordable Housing Law
COVID-19 Surge in Idaho Forcing Statewide Health Care Rationing
JPMorgan Launching Its First Overseas Digital Bank in United Kingdom Next Week
Federal Reserve Reviewing Ethics Policies in Wake of Prolific Trading Disclosed by Two Senior Officials
Chinese Property Developer Evergrande Not 'Too Big to Fail' — Global Times
August Retail Sales Rebound 0.7%, Surprising Economists After July Plunge
UN Report Shows COVID-19 Has Not Slowed Pace of Climate Change



Market Movers

Sponsored Financial Content